Survival Outcomes With Lu-177 PSMA by Treatment Line and Taxane Sequencing in Prostate Cancer - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Survival With Lu-177 PSMA Therapy in Prostate Cancer: Outcomes by Treatment Line and Taxane Sequence

  • By

  • Varun Nandakumar

  • Yeonjung Jo

  • Micah Ostrowski

  • Georges Gebrael

  • Zeynep Irem Ozay

  • Edwin Lin

  • Krishnam Goel

  • Rachel Revillo

  • Laxmi Upadhyay

  • Tejita Agarwal

  • Nicolas Sayegh

  • Vinay Mathew Thomas

  • Haoran Li

  • Neeraj Agarwal

  • Umang Swami

  • October 15, 2026

Share

  • 1

    This retrospective cohort study included 850 patients with metastatic androgen pathway modulator–resistant prostate cancer treated with Lu-177 PSMA.

  • 2

    Median clinical time to next treatment was 8.5 months, and median clinical overall survival was 13.0 months.

  • 3

    Lu-177 PSMA was administered in the third or fourth treatment line for 434 patients (51.1%).

  • 4

    Among patients with prior taxane exposure, median time to next treatment was 8.0 months and median overall survival was 12.0 months.

  • 5

    Among patients with no taxane exposure, median time to next treatment was 10.0 months and median overall survival was 14.0 months.

Original Source(s)

Survival Outcomes With Lu-177 PSMA by Treatment Line and Taxane Sequencing in Prostate Cancer

  • by Varun Nandakumar, Yeonjung Jo, Micah Ostrowski, Georges Gebrael, Zeynep Irem Ozay, Edwin Lin, Krishnam Goel, Rachel Revillo, Laxmi Upadhyay, Tejita Agarwal, Nicolas Sayegh, Vinay Mathew Thomas, Haoran Li, Neeraj Agarwal, Umang Swami

  • October 15, 2026

Related Content

Resection zone prediction for parenchyma-sparing hepatectomy planning: a comparative study of three modeling paradigms

Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments)

2026 ASCO Breast Cancer Highlights: PANKU-Breast02

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new results from the PANKU-Breast02 Study on a new dual-antibody drug conjugate, called izalontamab brengitecan (iza-bren), for metastatic triple-negative breast cancer.

  • October 15, 2026

  • 1 min